All lobbying filings

BGR Government Affairs

BGR Government Affairs filed a Q1 report for Regeneron Pharmaceuticals, Inc. on April 20, 2026, reporting $90,000 in lobbying income.

Lobbying for Regeneron Pharmaceuticals, Inc. · Pharmaceutical company

As filed: BGR GOVERNMENT AFFAIRS for REGENERON PHARMACEUTICALS, INC.

All filings by BGR Government Affairs · Everything Regeneron Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$90,000

What the client paid this registrant for the period.

Client based in

New York

Official filing document

Lobbyists on this filing 5

BRENT ALAN DEL MONTE

Previously held: Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee
RAGHAV AGGARWAL

Previously held: Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior
REMY LEIGH BRIM MASON

Previously held: Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz
DANIEL FARMER

Previously held: Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space
JOHN STONE

Previously held: Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.